For Q1 FY2026 ended March 31, 2026, COMPASS Pathways reported net income of $91.2 million, a 610.5% increase year-over-year, driven by a significant gain. Operating loss improved to $42.9 million, a 13.5% improvement. Diluted EPS was -$0.30, a 25% decline from the prior year. The company held $466.0 million in cash, $326.7 million in equity, and $50.5 million in long-term debt.
•Net income of $91.2 million, up 610.5% YoY.
•Operating loss of $42.9 million, improved 13.5% YoY.
•Diluted EPS of -$0.30, down 25% YoY.
•Cash of $466.0 million, equity of $326.7 million, long-term debt of $50.5 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
COMPASS Pathways is a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression
Is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. Incorporated in 2020 and headquartered in London, the United Kingdom, the company was formerly known as COMPASS Rx Limited before rebranding in August 2020.
COMPASS Pathways plc is a biotechnology company focused on mental health, operating in the United Kingdom and the United States. Its primary product is COMP360, a psilocybin therapy currently in Phase III clinical trials for treatment-resistant depression. The company is also investigating COMP360 in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS Pathways aims to address unmet needs in mental health care through innovative therapies. The company was formerly known as COMPASS Rx Limited before rebranding in August 2020.
Where is COMPASS Pathways (CMPS) listed and in which currency?
COMPASS Pathways plc is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CMPS. Its shares trade in US Dollars (USD), reflecting its primary listing on a US exchange. The company is headquartered in London, United Kingdom, but its stock is accessible to international investors through the Nasdaq. The choice of a US listing provides exposure to a broad investor base and aligns with its operations in the United States.
What sector and industry does COMPASS Pathways (CMPS) belong to?
COMPASS Pathways plc operates in the Healthcare sector, specifically within the Medical Care Facilities industry. This classification reflects its focus on developing therapies for mental health conditions, which are delivered through clinical settings. As a biotechnology company, it conducts research and clinical trials to bring new treatments to market. The Medical Care Facilities industry encompasses entities that provide medical services, and COMPASS Pathways' work with psilocybin therapy fits within this framework as it aims to offer novel care options for patients with mental health disorders.
Where is COMPASS Pathways (CMPS) headquartered and what markets does it serve?
COMPASS Pathways plc is headquartered in London, United Kingdom, and was incorporated in 2020. The company serves markets in the United Kingdom and the United States, focusing on mental health treatment. Its clinical trials for COMP360 are conducted in these regions, targeting conditions like treatment-resistant depression, PTSD, and anorexia nervosa. The company's operations span both countries, leveraging expertise from the UK and US healthcare systems. Despite being UK-based, its Nasdaq listing and US-focused trials highlight a significant presence in the American market.
What is COMP360 and what conditions does COMPASS Pathways (CMPS) target?
COMP360 is a proprietary psilocybin therapy developed by COMPASS Pathways plc. It is currently in Phase III clinical trials for treatment-resistant depression, a condition where patients do not respond to standard antidepressants. Additionally, COMP360 is being studied in Phase II trials for post-traumatic stress disorder (PTSD) and anorexia nervosa. Psilocybin is a psychedelic compound that, when administered in a controlled setting, may help reset neural pathways. COMPASS Pathways is pioneering this approach to address serious mental health conditions with limited treatment options, aiming to provide new hope for patients.